Rational Choice of Antibiotics and Media for Mycobacterium avium Complex Drug Susceptibility Testing

被引:10
|
作者
Jaffre, Jeremy [1 ,2 ]
Aubry, Alexandra [1 ,2 ]
Maitre, Thomas [1 ]
Morel, Florence [1 ,2 ]
Brossier, Florence [1 ,2 ]
Robert, Jerome [1 ,2 ]
Sougakoff, Wladimir [1 ,2 ]
Veziris, Nicolas [1 ,2 ,3 ]
机构
[1] Sorbonne Univ, Grp Hosp Univ, Hop Pitie Salpetriere, AP HP,Ctr Natl Reference Mycobacteries & Resistan, Paris, France
[2] Sorbonne Univ, INSERM, Cimi Paris, Ctr Immunol & Malad Infect,U1135, Paris, France
[3] Sorbonne Univ, Grp Hosp Univ, Hop St Antoine, AP HP, Paris, France
关键词
drug susceptibility testing; Mycobacterium avium complex; SLOMYCO Sensititre; Mueller Hinton; clarithromycin; amikacin; IN-VITRO ACTIVITY; RANDOMIZED-TRIAL; LUNG-DISEASE; CLARITHROMYCIN; THERAPY; COMBINATION; ETHAMBUTOL; RIFABUTIN; REGIMENS; AMIKACIN;
D O I
10.3389/fmicb.2020.00081
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The Clinical and Laboratory Standards Institute recommends the use of Mueller Hinton (MH) medium to perform drug susceptibility testing (DST) of Mycobacterium avium complex (MAC) using the microdilution method. For MAC, there has been no study on the impact of media on the determination of minimum inhibitory concentrations (MICs) of antibiotics other than clarithromycin. This study aimed at determining the impact of two media used for DST of MAC and at augmenting the number of pertinent MICs for MAC species encountered in clinical practice. MICs of antibiotics used for the treatment of MAC infections were determined for 158 clinical MAC isolates (80 M. avium, 40 M. intracellulare, 35 M. chimaera, two M. yongonense and one M. timonense) in MH and 7H9 broths using the SLOMYCO Sensititre(TM) system (TREK Diagnostic Systems, East Grinstead, United Kingdom). The modal MICs determined in both media were the same for linezolid, moxifloxacin, rifabutin and amikacin but not for clarithromycin, rifampin and ethambutol. The kappa test for MICs converted to susceptibility categories showed an excellent agreement for clarithromycin, a moderate agreement for linezolid and a weak agreement for moxifloxacin and amikacin. For amikacin, 7H9 allowed a better distinction (fewer intermediate strains) of wild-type populations than MH. Existing breakpoints for linezolid and moxifloxacin are spread through the distribution of MICs for wild-type populations. The only breakpoints that can be used rationally are those for amikacin and clarithromycin. For amikacin, 7H9 performs better than MH, whereas both media perform equally for clarithromycin. Given that testing in 7H9, as opposed to MH, allows easier MIC measurements and yields greater reproducibility, we propose the use of 7H9 medium for DST of MAC.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] QUANTITATIVE CULTURES AND DRUG SUSCEPTIBILITY TESTING OF MYCOBACTERIUM-AVIUM CLINICAL ISOLATES BEFORE AND DURING THE ANTIMICROBIAL THERAPY
    HEIFETS, LB
    RESEARCH IN MICROBIOLOGY, 1994, 145 (03) : 188 - 196
  • [42] Effect of efflux pump inhibitors on the susceptibility of Mycobacterium avium complex to clarithromycin
    Melissa Menichini
    Nicoletta Lari
    Laura Rindi
    The Journal of Antibiotics, 2020, 73 : 128 - 132
  • [43] Effect of efflux pump inhibitors on the susceptibility of Mycobacterium avium complex to clarithromycin
    Menichini, Melissa
    Lari, Nicoletta
    Rindi, Laura
    JOURNAL OF ANTIBIOTICS, 2020, 73 (02): : 128 - 132
  • [44] Identification of MICA as a Susceptibility Gene for Pulmonary Mycobacterium avium Complex Infection
    Shojima, Junko
    Tanaka, Goh
    Keicho, Naoto
    Tamiya, Gen
    Ando, Satoshi
    Oka, Akira
    Inoue, Yoshikazu
    Suzuki, Katsuhiro
    Sakatani, Mitsunori
    Okada, Masaji
    Kobayashi, Nobuyuki
    Toyota, Emiko
    Kudo, Koichiro
    Kajiki, Akira
    Nagai, Hideaki
    Kurashima, Atsuyuki
    Oketani, Norihiro
    Hayakawa, Hiroshi
    Takemura, Tamiko
    Nakata, Koh
    Ito, Hideyuki
    Morita, Takatomo
    Matsushita, Ikumi
    Hijikata, Minako
    Sakurada, Shinsaku
    Sasazuki, Takehiko
    Inoko, Hidetoshi
    JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (11): : 1707 - 1715
  • [45] The ESP culture system for drug susceptibilities of Mycobacterium avium complex
    Lui, AY
    LaBombardi, VJ
    Turett, GS
    Kislak, JW
    Nord, JA
    CLINICAL MICROBIOLOGY AND INFECTION, 2000, 6 (12) : 649 - 652
  • [46] Current perspectives on drug susceptibility testing of Mycobacterium tuberculosis complex:: the automated nonradiometric systems
    Piersimoni, C
    Olivieri, A
    Benacchio, L
    Scarparo, C
    JOURNAL OF CLINICAL MICROBIOLOGY, 2006, 44 (01) : 20 - 28
  • [47] Sensititre® MYCOTB MIC plate for drug susceptibility testing of Mycobacterium tuberculosis complex isolates
    Yu, X.
    Ma, Y. -F.
    Jiang, G. -L.
    Chen, S. -T.
    Wang, G. -R.
    Huang, H. -R.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2016, 20 (03) : 329 - 334
  • [48] Modification of results of drug susceptibility tests by coexistence of Mycobacterium avium complex with Mycobacterium tuberculosis in a sputum sample:: Case report and experimental considerations
    Suzuki, K
    Kimoto, T
    Tsuyuguchi, K
    Matsumoto, H
    Niimi, A
    Tanaka, E
    Murayama, T
    Amitani, R
    JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (09) : 2745 - 2747
  • [49] Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens
    Cho, Eun Hye
    Huh, Hee Jae
    Song, Dong Joon
    Moon, Seong Mi
    Lee, Seung-Heon
    Shin, So Youn
    Kim, Chang Ki
    Ki, Chang-Seok
    Koh, Won-Jung
    Lee, Nam Yong
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2018, 24 (04) : 315 - 318
  • [50] INVITRO SUSCEPTIBILITY OF MYCOBACTERIUM-FORTUITUM COMPLEX TO CEPHEM ANTIBIOTICS
    SAITO, H
    SATO, K
    HIROSHIMA JOURNAL OF MEDICAL SCIENCES, 1985, 34 (02) : 257 - 260